Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.

Diabetes Obes MetabJun 16, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Seyedeh Samira Rakhsha, Hossein Shahinfar, Sara Ebrahimi-Mousavi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the effects of major antidiabetic drugs on body composition in 2906 participants across 41 trials. Tirzepatide demonstrated the most significant reduction in fat mass (MD -10.70 kg; 95% CI: -13.42 to -7.99) compared to placebo, while also causing a notable decrease in lean body mass.

Key findings

  • Tirzepatide led to a fat mass reduction of -10.70 kg compared to placebo.
  • Liraglutide plus exercise mitigated lean body mass loss.
  • Insulin glargine and alogliptin were associated with fat mass gain.
  • SGLT2 inhibitors caused minor fat mass losses.

Why it matters

Understanding the differential effects of antidiabetic medications on body composition is crucial for optimizing treatment strategies, as these changes can influence metabolic health and patient outcomes.

Source

PubMed · PMID 42304171Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.